Transcriptome analysis of ovaries by subcutaneous injections of olaparib in wild-type and BRCA1+/- rats.

BRCA1 pathogenic variant may have the negative impact on ovarian function. Poly (adenosine diphosphate–ribose) polymerase (PARP) inhibitor, olaparib exploit the principle of synthetic lethality to selectively kill the cells that have a deficiency in homologous recombination repair. To evaluate the effect to olaparib on ovaries, we performed the study of subcutaneous olaparib injections for 2 weeks in wild-type and BRCA1+/- rats. We compared the microarray gene expression profiles of rat ovary tissues from the study. The olaparib protocol in ovaries was started with 8 wildtype and 8 BRCA1+/- female Jcl: SD rats. A total of 16 microarrays (Whole Rat Genome Microarray) were used for screening purpose: 8 microarrays for wildtype SD rats, and 8 for BRCA1+/- SD rats.